Peter Luo Biography and Net Worth

CEO of Adagene

Mr. Peter Luo is our Co-Founder and has served as our Chief Executive Officer since November 2011 and Chairman of the Board of the Directors since February 2018. Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor (Nasdaq: XNCR) from July 1998 to August 2000. In September 2000, Dr. Luo founded Abmaxis Inc. and served as its Co-Founder, Chief Technology Officer, president, and director. In May 2006, Dr. Luo led the acquisition of Abmaxis Inc. by Merck & Co. (NYSE: MRK), after which Dr. Luo served as a director of Biologics Technology at Merck, and Chief Technology Officer of Abmaxis, the subsidiary of Merck & Co. Throughout his career, Dr. Luo also led the business development efforts in connection with collaborations and strategic partnerships with multiple global partners. Dr. Luo received his bachelor’s degree in applied chemistry in technical physics from Peking University in 1986, master’s degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences in 1989, and Ph.D. degree in chemistry from The University of Chicago in 1995. Dr. Luo also completed his postdoctoral research in protein folding at Stanford University in 1998.

What is Peter Luo's net worth?: The estimated net worth of Peter Luo is at least $275.10 thousand as of August 5th, 2026. Dr. Luo owns 68,245 shares of Adagene stock worth more than $275,096 as of August 10th. This net worth estimate does not reflect any other assets that Dr. Luo may own. Learn More about Peter Luo's net worth.
How do I contact Peter Luo?: The corporate mailing address for Dr. Luo and other Adagene executives is 4F BUILDING C14 NO. 218 XINGHU STREET SUZHOU INDUSTRIAL PARK, JIANGSU F4, 215123. Adagene can also be reached via phone at 86-512-8777-3632 and via email at [email protected]. Learn More on Peter Luo's contact information.
Has Peter Luo been buying or selling shares of Adagene?: In the last ninety days, Peter Luo has bought $84,844.25 in shares of Adagene stock. Most recently, on Wednesday, August 5th, Peter Luo bought 279 shares of Adagene stock. The stock was acquired at an average cost of $3.65 per share, with a total value of $1,018.35. Following the completion of the transaction, the chief executive officer now directly owns 68,245 shares of the company's stock, valued at $249,094.25. Learn More on Peter Luo's trading history.
Are insiders buying or selling shares of Adagene?: In the last twelve months, Adagene insiders bought shares 2 times. They purchased a total of 23,245 shares worth more than $84,844.25. The most recent insider tranaction occured on August, 5th when CEO Peter Luo bought 279 shares worth more than $1,018.35. Insiders at Adagene own 21.2% of the company. Learn More about insider trades at Adagene.
Information on this page was last updated on 8/5/2026.

Peter Luo Insider Trading History at Adagene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/5/2026	Buy	279	$3.65	$1,018.35	68,245
8/4/2026	Buy	22,966	$3.65	$83,825.90	67,966

Peter Luo Buying and Selling Activity at Adagene

Adagene Company Overview

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Today's Range

Now: $4.11

$3.95

$4.17

50 Day Range

MA: $3.78

$3.20

$4.78

2 Week Range

Now: $4.11

$1.30

$4.85

Volume

489,910 shs

Average Volume

233,132 shs

Market Capitalization

$194.54 million

P/E Ratio

N/A

Dividend Yield